Toll-like receptor, lipotoxicity and chronic inflammation: The pathological link between obesity and cardiometabolic disease

Journal of Atherosclerosis and Thrombosis

Volumn 21, Issue 7, 2014, Pages 629-639

  Eguchi, Kosei ^a,b   Manabe, Ichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Atherosclerosis; Free fatty acids; Inflammation; Metabolic syndrome; Toll like receptor

Indexed keywords

TOLL LIKE RECEPTOR;

ANIMAL; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; HEART DISEASE; HUMAN; INFLAMMATION; METABOLIC SYNDROME X; METABOLISM; OBESITY; PATHOLOGY;

ADIPOSITY; ANIMALS; HEART DISEASES; HUMANS; INFLAMMATION; LIPID METABOLISM DISORDERS; METABOLIC SYNDROME X; OBESITY; TOLL-LIKE RECEPTORS;

EID: 84905163411     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.22533     Document Type: Review

References (78)

1. Ross R: Atherosclerosis--an inflammatory disease. N Engl J Med, 1999; 340: 115-126
2. Mayerl C, Lukasser M, Sedivy R, Niederegger H, Seiler R, Wick G: Atherosclerosis research from past to present--on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch, 2006; 449: 96-103
3. Williamson RT: On the treatment of glycosuria and diabetes mellitus with sodium salicylate. Br Med J, 1901; 1: 760-762
4. Couzin-Frankel J: Inflammation bares a dark side. Science, 2010; 330: 1621
5. Donath MY, Shoelson SE: Type 2 diabetes as an inflammatory disease. Nat Rev Immunol, 2011; 11: 98-107
6. Pearce EL, Pearce EJ: Metabolic pathways in immune cell activation and quiescence. Immunity, 2013; 38: 633-643
7. Mathis D, Shoelson SE: Immunometabolism: an emerging frontier. Nat Rev Immunol, 2011; 11: 81
8. Hedayat M, Mahmoudi MJ, Rose NR, Rezaei N: Proinflammatory cytokines in heart failure: double-edged swords. Heart Fail Rev, 2010; 15: 543-562
9. Abd T, Eapen D, Bajpai A, Goyal A, Dollar A, Sperling L: The role of C-reactive protein as a risk predictor of coronary atherosclerosis: implications from the JUPITER trial. Curr Atheroscler Rep, 2011; 13: 154-161
10. Schmidt MI, Duncan BB, Sharrett AR, Lindberg G, Savage PJ, Offenbacher S, Azambuja MI, Tracy RP, Heiss G: Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): a cohort study. Lancet, 1999; 353: 1649-1652
11. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM: C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001; 286: 327-334
12. Haffner S, Temprosa M, Crandall J, Fowler S, Goldberg R, Horton E, Marcovina S, Mather K, Orchard T, Ratner R, Barrett-Connor E, Diabetes Prevention Program Research G: Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes, 2005; 54: 1566-1572
13. Matsuzawa Y: Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci, 2010; 86: 131-141
14. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K: Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest, 2006; 116: 1784-1792
15. Oike Y, Tabata M: Angiopoietin-like proteins--potential therapeutic targets for metabolic syndrome and cardiovascular disease. Circ J, 2009; 73: 2192-2197
16. Tilg H, Moschen AR: Inflammatory mechanisms in the regulation of insulin resistance. Mol Med, 2008; 14: 222-231
17. Hotamisligil GS, Shargill NS, Spiegelman BM: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993; 259: 87-91
18. Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, Gueripel X, Ellingsgaard H, Schneider MK, Biollaz G, Fontana A, Reinecke M, Homo-Delarche F, Donath MY: Increased number of islet-associated macrophages in type 2 diabetes. Diabetes, 2007; 56: 2356-2370
19. Eguchi K, Manabe I, Oishi-Tanaka Y, Ohsugi M, Kono N, Ogata F, Yagi N, Ohto U, Kimoto M, Miyake K, Tobe K, Arai H, Kadowaki T, Nagai R: Saturated fatty acid and TLR signaling link beta cell dysfunction and islet inflammation. Cell Metab, 2012; 15: 518-533
20. Gillingham LG, Harris-Janz S, Jones PJ: Dietary monounsaturated fatty acids are protective against metabolic syndrome and cardiovascular disease risk factors. Lipids, 2011; 46: 209-228
21. Robinson LE, Mazurak VC: N-3 polyunsaturated fatty acids: relationship to inflammation in healthy adults and adults exhibiting features of metabolic syndrome. Lipids, 2013; 48: 319-332
22. Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K, Japan EPAlisI: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098
23. Stover AG, Da Silva Correia J, Evans JT, Cluff CW, Elliott MW, Jeffery EW, Johnson DA, Lacy MJ, Baldridge JR, Probst P, Ulevitch RJ, Persing DH, Hershberg RM: Structure-activity relationship of synthetic toll-like receptor 4 agonists. J Biol Chem, 2004; 279: 4440-4449
24. Lee JY, Sohn KH, Rhee SH, Hwang D: Saturated fatty acids, but not unsaturated fatty acids, induce the expression of cyclooxygenase-2 mediated through Toll-like receptor 4. J Biol Chem, 2001; 276: 16683-16689
25. Lee JY, Zhao L, Youn HS, Weatherill AR, Tapping R, Feng L, Lee WH, Fitzgerald KA, Hwang DH: Saturated fatty acid activates but polyunsaturated fatty acid inhibits Toll-like receptor 2 dimerized with Toll-like receptor 6 or 1. J Biol Chem, 2004; 279: 16971-16979
26. Kim F, Pham M, Luttrell I, Bannerman DD, Tupper J, Thaler J, Hawn TR, Raines EW, Schwartz MW: Toll-like receptor-4 mediates vascular inflammation and insulin resistance in diet-induced obesity. Circ Res, 2007; 100: 1589-1596
27. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS: TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest, 2006; 116: 3015-3025
28. Oh SR, Sul OJ, Kim YY, Kim HJ, Yu R, Suh JH, Choi HS: Saturated fatty acids enhance osteoclast survival. J Lipid Res, 2010; 51: 892-899
29. Erridge C, Samani NJ: Saturated fatty acids do not directly stimulate Toll-like receptor signaling. Arterioscler Thromb Vasc Biol, 2009; 29: 1944-1949
30. Huang S, Rutkowsky JM, Snodgrass RG, Ono-Moore KD, Schneider DA, Newman JW, Adams SH, Hwang DH: Saturated fatty acids activate TLR-mediated proinflammatory signaling pathways. J Lipid Res, 2012; 53: 2002-2013
31. Pal D, Dasgupta S, Kundu R, Maitra S, Das G, Mukhopadhyay S, Ray S, Majumdar SS, Bhattacharya S: Fetuin-A acts as an endogenous ligand of TLR4 to promote lipidinduced insulin resistance. Nat Med, 2012; 18: 1279-1285
32. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J: Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol, 1999; 34: 1975-1981
33. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Makela PH, Huttunen JK and Valtonen V: Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet, 1988; 2: 983-986
34. Cani PD, Possemiers S, Van de Wiele T, Guiot Y, Everard A, Rottier O, Geurts L, Naslain D, Neyrinck A, Lambert DM, Muccioli GG, Delzenne NM: Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut, 2009; 58: 1091-1103
35. Brun P, Castagliuolo I, Di Leo V, Buda A, Pinzani M, Palu G, Martines D: Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. Am J Physiol Gastrointest Liver Physiol, 2007; 292: G518-525
36. Imajo K, Fujita K, Yoneda M, Nozaki Y, Ogawa Y, Shinohara Y, Kato S, Mawatari H, Shibata W, Kitani H, Ikejima K, Kirikoshi H, Nakajima N, Saito S, Maeyama S, Watanabe S, Wada K, Nakajima A: Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab, 2012; 16: 44-54
37. Wright SD, Burton C, Hernandez M, Hassing H, Montenegro J, Mundt S, Patel S, Card DJ, Hermanowski-Vosatka A, Bergstrom JD, Sparrow CP, Detmers PA, Chao YS: Infectious agents are not necessary for murine atherogenesis. J Exp Med, 2000; 191: 1437-1442
38. Miller YI, Viriyakosol S, Binder CJ, Feramisco JR, Kirkland TN, Witztum JL: Minimally modified LDL binds to CD14, induces macrophage spreading via TLR4/MD-2, and inhibits phagocytosis of apoptotic cells. J Biol Chem, 2003; 278: 1561-1568
39. Shi W, Haberland ME, Jien ML, Shih DM, Lusis AJ: Endothelial responses to oxidized lipoproteins determine genetic susceptibility to atherosclerosis in mice. Circulation, 2000; 102: 75-81
40. Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, Yeh M, Cole AL, Berliner JA: Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositolanchored protein. J Biol Chem, 2003; 278: 29661-29666
41. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Hacker H, Wagner H: Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem, 2001; 276: 31332-31339
42. Sasu S, LaVerda D, Qureshi N, Golenbock DT, Beasley D: Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res, 2001; 89: 244-250
43. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J: Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med, 2007; 13: 1042-1049
44. Averill MM, Barnhart S, Becker L, Li X, Heinecke JW, Leboeuf RC, Hamerman JA, Sorg C, Kerkhoff C, Bornfeldt KE: S100A9 differentially modifies phenotypic states of neutrophils, macrophages, and dendritic cells: implications for atherosclerosis and adipose tissue inflammation. Circulation, 2011; 123: 1216-1226
45. Hodgkinson CP, Laxton RC, Patel K, Ye S: Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis. Arterioscler Thromb Vasc Biol, 2008; 28: 2275-2281
46. Kawai T, Akira S: Signaling to NF-kappaB by Toll-like receptors. Trends Mol Med, 2007; 13: 460-469
47. Beutler B, Rietschel ET: Innate immune sensing and its roots: the story of endotoxin. Nat Rev Immunol, 2003; 3: 169-176
48. Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, Araujo EP, Vassallo J, Curi R, Velloso LA, Saad MJ: Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes, 2007; 56: 1986-1998
49. Poggi M, Bastelica D, Gual P, Iglesias MA, Gremeaux T, Knauf C, Peiretti F, Verdier M, Juhan-Vague I, Tanti JF, Burcelin R, Alessi MC: C3H/HeJ mice carrying a toll-like receptor 4 mutation are protected against the development of insulin resistance in white adipose tissue in response to a high-fat diet. Diabetologia, 2007; 50: 1267-1276
50. Suganami T, Mieda T, Itoh M, Shimoda Y, Kamei Y, Ogawa Y: Attenuation of obesity-induced adipose tissue inflammation in C3H/HeJ mice carrying a Toll-like receptor 4 mutation. Biochem Biophys Res Commun, 2007; 354: 45-49
51. Suganami T, Tanimoto-Koyama K, Nishida J, Itoh M, Yuan X, Mizuarai S, Kotani H, Yamaoka S, Miyake K, Aoe S, Kamei Y, Ogawa Y: Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol, 2007; 27: 84-91
52. Yu C, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, Bergeron R, Kim JK, Cushman SW, Cooney GJ, Atcheson B, White MF, Kraegen EW, Shulman GI: Mechanism by which fatty acids inhibit insulin activation of insulin receptor substrate-1 (IRS-1)-associated phosphatidylinositol 3-kinase activity in muscle. J Biol Chem, 2002; 277: 50230-50236
53. Boden G: Obesity, insulin resistance and free fatty acids. Curr Opin Endocrinol Diabetes Obes, 2011; 18: 139-143
54. Cnop M: Fatty acids and glucolipotoxicity in the pathogenesis of Type 2 diabetes. Biochem Soc Trans, 2008; 36: 348-352
55. Fonseca SG, Gromada J, Urano F: Endoplasmic reticulum stress and pancreatic beta-cell death. Trends in endocrinology and metabolism: Trends Endocrinol Metab, 2011; 22: 266-274
56. Cucak H, Grunnet LG, Rosendahl A: Accumulation of M1-like macrophages in type 2 diabetic islets is followed by a systemic shift in macrophage polarization. J Leuk Biol, 2014; doi: 10.1189/jlb.0213075
57. Jourdan T, Godlewski G, Cinar R, Bertola A, Szanda G, Liu J, Tam J, Han T, Mukhopadhyay B, Skarulis MC, Ju C, Aouadi M, Czech MP, Kunos G: Activation of the Nlrp3 inflammasome in infiltrating macrophages by endocannabinoids mediates beta cell loss in type 2 diabetes. Nat Med, 2013; 19: 1132-1140
58. Li J, Chen L, Zhang Y, Zhang WJ, Xu W, Qin Y, Xu J, Zou D: TLR4 is required for the obesity-induced pancreatic beta cell dysfunction. Acta Biochim Biophys, 2013; 45: 1030-1038
59. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA: Toll-like receptor 4 polymorphisms and atherogenesis. N Eng J Med, 2002; 347: 185-192
60. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, Lamotte M, Lebret D, Ollivier V, de Prost D: Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol, 2003; 23: e61-64
61. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M: Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc Natl Acad Sci U S A, 2004; 101: 10679-10684
62. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med, 2004; 10: 416-421
63. Mullick AE, Soldau K, Kiosses WB, Bell TA, 3rd, Tobias PS, Curtiss LK: Increased endothelial expression of Tolllike receptor 2 at sites of disturbed blood flow exacerbates early atherogenic events. J Exp Med, 2008; 205: 373-383
64. Mullick AE, Tobias PS, Curtiss LK: Modulation of atherosclerosis in mice by Toll-like receptor 2. J Clin Invest, 2005; 115: 3149-3156
65. Seimon TA, Nadolski MJ, Liao X, Magallon J, Nguyen M, Feric NT, Koschinsky ML, Harkewicz R, Witztum JL, Tsimikas S, Golenbock D, Moore KJ, Tabas I: Atherogenic lipids and lipoproteins trigger CD36-TLR2-dependent apoptosis in macrophages undergoing endoplasmic reticulum stress. Cell Metab 2010; 12: 467-482
66. Lundberg AM, Ketelhuth DF, Johansson ME, Gerdes N, Liu S, Yamamoto M, Akira S, Hansson GK: Toll-like receptor 3 and 4 signalling through the TRIF and TRAM adaptors in haematopoietic cells promotes atherosclerosis. Cardiovasc Res, 2013; 99: 364-373
67. Hayashi C, Papadopoulos G, Gudino CV, Weinberg EO, Barth KR, Madrigal AG, Chen Y, Ning H, LaValley M, Gibson FC, 3rd, Hamilton JA, Genco CA: Protective role for TLR4 signaling in atherosclerosis progression as revealed by infection with a common oral pathogen. J Immunol, 2012; 189: 3681-3688
68. Subramanian M, Thorp E, Hansson GK, Tabas I: Tregmediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest, 2013; 123: 179-188
69. Hooper L, Summerbell CD, Thompson R, Sills D, Roberts FG, Moore HJ, Davey Smith G: Reduced or modified dietary fat for preventing cardiovascular disease. Cochrane Database Syst Rev, 2012; 5: CD002137
70. Kim F, Tysseling KA, Rice J, Pham M, Haji L, Gallis BM, Baas AS, Paramsothy P, Giachelli CM, Corson MA, Raines EW: Free fatty acid impairment of nitric oxide production in endothelial cells is mediated by IKKbeta. Arterioscler Thromb Vasc Biol, 2005; 25: 989-994
71. Staiger H, Staiger K, Stefan N, Wahl HG, Machicao F, Kellerer M, Haring HU: Palmitate-induced interleukin-6 expression in human coronary artery endothelial cells. Diabetes, 2004; 53: 3209-3216
72. Krogmann A, Staiger K, Haas C, Gommer N, Peter A, Heni M, Machicao F, Haring HU, Staiger H: Inflammatory response of human coronary artery endothelial cells to saturated long-chain fatty acids. Microvasc Res, 2011; 81: 52-59
73. Maloney E, Sweet IR, Hockenbery DM, Pham M, Rizzo NO, Tateya S, Handa P, Schwartz MW, Kim F: Activation of NF-kappaB by palmitate in endothelial cells: a key role for NADPH oxidase-derived superoxide in response to TLR4 activation. Arterioscler Thromb Vasc Biol, 2009; 29: 1370-1375
74. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, Imamura M, Aoki T, Etoh T, Hashimoto T, Naruse M, Sano H, Utsumi H, Nawata H: High glucose level and free fatty acid stimulate reactive oxygen species production through protein kinase C--dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes, 2000; 49: 1939-1945
75. Rodriguez-Lee M, Ostergren-Lunden G, Wallin B, Moses J, Bondjers G, Camejo G: Fatty acids cause alterations of human arterial smooth muscle cell proteoglycans that increase the affinity for low-density lipoprotein. Arterioscler Thromb Vasc Biol, 2006; 26: 130-135
76. Shen H, Eguchi K, Kono N, Fujiu K, Matsumoto S, Shibata M, Oishi-Tanaka Y, Komuro I, Arai H, Nagai R, Manabe I: Saturated fatty acid palmitate aggravates neointima formation by promoting smooth muscle phenotypic modulation. Arterioscler Thromb Vasc Biol, 2013; 33: 2596-2607
77. Chung JH, Jeon HJ, Hong SY, Lee da L, Lee KH, Kim SH, Han YS, Manabe I, Miller YI, Lee SH: Palmitate promotes the paracrine effects of macrophages on vascular smooth muscle cells: the role of bone morphogenetic proteins. Plos One, 2012; 7: e29100
78. Weinberg JM: Lipotoxicity. Kidey Int, 2006; 70: 1560-1566